Statins and autoimmune diseases

P. Riboldi, M. Gerosa, Pier Luigi Meroni

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Besides the well-known lipid-lowering effect, statins display nonlipid-lowering pharmacological activities. In vitro and in vivo studies suggest that statins have direct anti-inflammatory, antithrombotic and plaque-stabilizing effects via a number of mechanisms. A direct immunomodulatory effect has been also demonstrated in in vitro and in vivo experimental models. In addition to traditional risk factors, systemic inflammation, immune-mediated responses and thrombophilia have been suggested to play a major role in sustaining the premature atherosclerosis in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. This review focuses on the anti-inflammatory and immunomodulating mechanisms of statins as demonstrated in in vitro and in vivo experimental models, providing new insights for the use of statins in treating systemic autoimmune diseases both for their anti-atherosclerotic activity and for their pleiotropic effects on inflammation, haemostasis and the immune responses.

Original languageEnglish
Pages (from-to)765-768
Number of pages4
JournalLupus
Volume14
Issue number9
DOIs
Publication statusPublished - 2005

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Autoimmune Diseases
Anti-Inflammatory Agents
Theoretical Models
Inflammation
Thrombophilia
Hemostasis
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Atherosclerosis
Pharmacology
Lipids
In Vitro Techniques

Keywords

  • Atherosclerosis
  • Autoimmune diseases
  • Immunomodulation
  • Inflammation
  • Statins

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Statins and autoimmune diseases. / Riboldi, P.; Gerosa, M.; Meroni, Pier Luigi.

In: Lupus, Vol. 14, No. 9, 2005, p. 765-768.

Research output: Contribution to journalArticle

Riboldi, P, Gerosa, M & Meroni, PL 2005, 'Statins and autoimmune diseases', Lupus, vol. 14, no. 9, pp. 765-768. https://doi.org/10.1191/0961203305lu2217oa
Riboldi, P. ; Gerosa, M. ; Meroni, Pier Luigi. / Statins and autoimmune diseases. In: Lupus. 2005 ; Vol. 14, No. 9. pp. 765-768.
@article{4627e664679348fe8abea532ac8aa963,
title = "Statins and autoimmune diseases",
abstract = "Besides the well-known lipid-lowering effect, statins display nonlipid-lowering pharmacological activities. In vitro and in vivo studies suggest that statins have direct anti-inflammatory, antithrombotic and plaque-stabilizing effects via a number of mechanisms. A direct immunomodulatory effect has been also demonstrated in in vitro and in vivo experimental models. In addition to traditional risk factors, systemic inflammation, immune-mediated responses and thrombophilia have been suggested to play a major role in sustaining the premature atherosclerosis in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. This review focuses on the anti-inflammatory and immunomodulating mechanisms of statins as demonstrated in in vitro and in vivo experimental models, providing new insights for the use of statins in treating systemic autoimmune diseases both for their anti-atherosclerotic activity and for their pleiotropic effects on inflammation, haemostasis and the immune responses.",
keywords = "Atherosclerosis, Autoimmune diseases, Immunomodulation, Inflammation, Statins",
author = "P. Riboldi and M. Gerosa and Meroni, {Pier Luigi}",
year = "2005",
doi = "10.1191/0961203305lu2217oa",
language = "English",
volume = "14",
pages = "765--768",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - Statins and autoimmune diseases

AU - Riboldi, P.

AU - Gerosa, M.

AU - Meroni, Pier Luigi

PY - 2005

Y1 - 2005

N2 - Besides the well-known lipid-lowering effect, statins display nonlipid-lowering pharmacological activities. In vitro and in vivo studies suggest that statins have direct anti-inflammatory, antithrombotic and plaque-stabilizing effects via a number of mechanisms. A direct immunomodulatory effect has been also demonstrated in in vitro and in vivo experimental models. In addition to traditional risk factors, systemic inflammation, immune-mediated responses and thrombophilia have been suggested to play a major role in sustaining the premature atherosclerosis in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. This review focuses on the anti-inflammatory and immunomodulating mechanisms of statins as demonstrated in in vitro and in vivo experimental models, providing new insights for the use of statins in treating systemic autoimmune diseases both for their anti-atherosclerotic activity and for their pleiotropic effects on inflammation, haemostasis and the immune responses.

AB - Besides the well-known lipid-lowering effect, statins display nonlipid-lowering pharmacological activities. In vitro and in vivo studies suggest that statins have direct anti-inflammatory, antithrombotic and plaque-stabilizing effects via a number of mechanisms. A direct immunomodulatory effect has been also demonstrated in in vitro and in vivo experimental models. In addition to traditional risk factors, systemic inflammation, immune-mediated responses and thrombophilia have been suggested to play a major role in sustaining the premature atherosclerosis in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. This review focuses on the anti-inflammatory and immunomodulating mechanisms of statins as demonstrated in in vitro and in vivo experimental models, providing new insights for the use of statins in treating systemic autoimmune diseases both for their anti-atherosclerotic activity and for their pleiotropic effects on inflammation, haemostasis and the immune responses.

KW - Atherosclerosis

KW - Autoimmune diseases

KW - Immunomodulation

KW - Inflammation

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=26244436457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244436457&partnerID=8YFLogxK

U2 - 10.1191/0961203305lu2217oa

DO - 10.1191/0961203305lu2217oa

M3 - Article

C2 - 16218484

AN - SCOPUS:26244436457

VL - 14

SP - 765

EP - 768

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 9

ER -